Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program

Voyager Therapeutics announced a new wholly-owned Alzheimer's disease (AD) program targeting apolipoprotein E (APOE), a major genetic risk factor for ...
Home/KnloSights/Clinical Trial Updates/Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program